Faculty

Piyush K. Agarwal, MD
Professor of Surgery and Urology, Director, Bladder Cancer Program Fellowship, Director, Urologic Oncology Comprehensive Cancer Research Center, The University of Chicago
Chicago, IL

Hamed Ahmadi, MD
Assistant Professor University of Minnesota
Minneapolis, MN

Omar Alhalabi, MD
Assistant Professor Department of Genitourinary Medical Oncology Division of Cancer Medicine UT MD Anderson Cancer Center
Houston, TX

Gustavo Ayala, MD
Professor Vice Chair, Outreach Department of Pathology and Laboratory Medicine UT Health Houston
Houston, TX

Mark W. Ball, MD
Associate Research Physician Urologic Oncology Branch Associate Director, Urologic Oncology Fellowship National Cancer Institute
Bethesda, MD

Arnab Basu, MD
Chief, Genitourinary Oncology, UAB O’Neal Comprehensive Cancer Center
Interim Chief, Genitourinary Oncology, UAB O’Neal Comprehensive Cancer Center
Assistant Professor, Genitourinary Oncology, UAB O’Neal Comprehensive Cancer Center Associate Scientist, UAB O’Neal Comprehensive Cancer Center
Birmingham, AL 

David J. Benjamin, MD
Medical Oncologist
Hoag Family Cancer Institute
Newport Beach, CA

Mehmet Bilen, MD​
Associate Professor, Department of Hematology and Medical Oncology​
Emory University School of Medicine​
Director, Genitourinary Medical Oncology Program​ Winship Cancer Institute of Emory University​
Atlanta, GA

Jacqueline T. Brown, MD
Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine Genitourinary Oncologist Winship Cancer
Institute of Emory University
Atlanta, GA

Manojkumar Bupathi, MD, MS
Medical Oncologist Rocky Mountain Cancer Centers Executive Co-Chair GU Research- Sarah Cannon Research Institute
Aurora, CO ​

Maria Carlo, MD
Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
New York, NY

Sant P. Chawla, MD
Director,  Sarcoma Oncology Center Santa
Monica, CA

Jonathan Chou, MD, PhD
Assistant Professor of Medicine, Department of Medicine University of California, San Francisco
San Francisco, CA

​​​​​​​Matthew Dallos, MD
Genitourinary Oncologist
Assistant Attending Physician
Department of Medicine
Solid Tumor Genito-Urinary Service
Memorial Sloan Kettering Cancer Center
New York, NY

Siamak Daneshmand, MD
Professor of Urology and Medicine (Oncology) -Clinical Scholar Director of Urologic Oncology Director of Clinical Research Urologic Oncology Fellowship Director USC/Norris Comprehensive Cancer Center

David Einstein, MD
Assistant Professor of Medicine Beth Israel Deaconess Medical Center
Boston MA

Scott Eggener, MD
Bruce and Beth White Family Professor of Surgery
Vice Chair, Section of Urology Director, High Risk and Advanced Prostate Cancer Clinic
The University of Chicago
Chicago, IL 

Hamid Emamekhoo, MD
Associate Professor of Medicine, Division of Hematology and Medical Oncology, Director of Clinical Cancer Research Informatics, University of Wisconsin Carbone Cancer Center
Madison, WI

Benjamin Garmezy, MD
Associate Director, Genitourinary Research Program
Co-Chair, GU Executive Committee, SCRI Network Sarah Cannon Research Institute GU Medical Oncologist and Investigator SCRI Oncology Partners
Nashville, TN

​​​​​Giannicola Genovese, MD, PhD
Associate Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, UT MD Anderson Cancer Center
Houston, TX

​​​​​Saby George, MD, FACP
Professor of Oncology
Director of Network Clinical Trials
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, NY

Julie Graff, MD
Staff Oncologist, VA Portland Health Care System Director of PATCH (Prostate cancer Analysis for Therapy CHoice) Professor, Hematology & Medical Oncology OHSU Knight Cancer Institute
Portland, OR

Scott Haake, MD, PhD
Assistant Professor, Division of Hematology & Oncology Department of Medicine, Vanderbilt University
Medical Center
Nashville, TN

Michael C. Haffner, MD, PhD
Assistant Professor, Pathology Human Biology, Division Clinical Research, Division Fred Hutchinson Cancer Center, Assistant Professor, Pathology, University of Washington School of Medicine
Seattle, WA

Raquibul Hannan, MD, PhD
Professor, Radiation Oncology, Urology and Immunology Chief, Genitourinary Radiation Oncology UT Southwestern Medical Center
Dallas, TX

Michael R. Harrison, MD
Associate Professor of Medicine Member of the Duke Cancer Institute, Duke University
Durham, NC

Jim C. Hu, MD, MPH
Ronald P. Lynch, Professor of Urologic Oncology Professor of Urology Weill Cornell Medicine
New York, NY

​​​​​Eric Jonasch, MD
Professor Department of Genitourinary Medical Oncology Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Houston, TX 

Joseph W. Kim, MD
Associate Professor of Medicine (Medical Oncology), Yale School of Medicine Director of Prostate Cancer Research for GU DART, Yale Cancer Center
New Haven, CT

Joseph W. Kim, MD
Associate Professor of Medicine (Medical Oncology), Yale School of Medicine Director of Prostate Cancer Research for GU DART, Yale Cancer Center
New Haven, CT

Manish Kohli, MD​
Professor, Division of Oncology, School of Medicine​
Jack R. and Hazel M. Robertson Presidential Endowed Chair​ Huntsman Cancer Institute​
Salt Lake City, UT

Kristine Peregrino Lacuna, MD
Assistant Attending, Memorial Sloan Kettering
Cancer Center
New York, NY

Elaine Lam, MD
Professor of Medicine​ School of Medicine​, Department of Medicine,​ Division of Medical Oncology,​ University of Colorado Anschutz Medical Campus​
Aurora, CO 

Andrew T. Lenis, MD
Assistant Professor of Urology, Department of Urology Columbia University, Irving Medical Center
New York, NY 

Seth Paul Lerner, MD, FACS
Professor of Urology, Beth and Dave Swalm
Chair in Urologic Oncology,  Director of Urologic Oncology Director of the Multidisciplinary Bladder Cancer Program Baylor College of Medicine
Houston, TX 

Paul Lin, MD, PhD
Assistant Professor of Medicine
UT MD Anderson Cancer Center
Houston, TX

Charlene Mantia, MD
Lank Center for Genitourinary Oncology Center for Cancer Therapeutic Innovation Department of Medical Oncology Dana-Farber Cancer Institute
Boston, MA

Nataliya Mar, MD
HS Associate Clinical Professor Division of Hematology/Oncology, Department of Medicine,  School of Medicine,  Chao Family Comprehensive Cancer Center,  UCI Health
Orange, CA 

​​​Vitaly Margulis, MD
Professor of Urology Paul C. Peters, M.D.,
Chair in Urology
UT Southwestern Medical Center
Dallas, TX

​​​Catherine Handy Marshall, MD, MPH
Assistant Professor, Department of Oncology Sidney Kimmel Cancer Comprehensive Cancer Center
Attending Physician, Oncology Johns Hopkins University Baltimore, MD

Hannah Dzimitrowicz McManus, MD
Assistant Professor of Medicine, Duke University School of Medicne
Durham, NC

Richard A. Miller, MD
CEO Corvus Pharmaceuticals Inc
Burlingame, CA

​​Matthew I. Milowsky, MD, FASCO
The George Gabriel and Frances Gable Villere Distinguished Professor of Medicine Section
Chief, Genitourinary Oncology
Vice Chief for Research & Education UNC Lineberger Comprehensive Cancer Center
The University of North Carolina
Chapel Hill, NC

Alicia Morgans, MD, MPH
Medical Director, Survivorship Program, Dana-Farber Cancer Institute, Associate Professor of Medicine Harvard Medical School
Boston, MA

Mohit Narang, MD
MOH chairman for P and T committee Maryland Oncology Hematology
Columbia,MD

Hao G. Nguyen, MD, PhD
Associate Professor in Residence; Urologic Oncology Richard and Leilani Grinold Endowed Professorship in Urology UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Peter H. O’Donnell, MD
Associate Professor of Medicine Section of Hematology / Oncology, Committee Chair, Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago
Chicago, IL 

David Oh, MD, PhD
Assistant Professor, Medicine Principal Investigator Assistant Professor In Residence, University of California San Francisco
San Francisco, CA

Akash Patnaik, MD, PhD
Associate Professor of Medicine Deputy Section
Chief for Translational Research Section of Hematology/Oncology Program Leader, Clinical & Experimental Therapeutics Program
University of Chicago Comprehensive Cancer Center
Chicago, IL

Mamta Parikh, MD, MS
Associate Professor, UC Davis School of Medicine Department of Internal Medicine, Division of Hematology Oncology, Medical Director, Genitourinary Malignancies Associate Director of Curriculum Affairs, ARC-MD UC Davis Comprehensive Cancer Center
Sacramento, CA

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology​ Chief, Genitourinary Oncology​
Director of Genitourinary Oncology,
Co Director Signal Transduction Program​
Yale School of Medicine​
New Haven, CT

Qian Qin, MD
Assistant Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, TX

​​Arlene Siefker-Radtke, MD
Professor, Genitourinary Medical Oncology
UT MD Anderson Cancer Center
Houston, TX

Melissa A. Reimers, MD
Associate Professor of Medicine, Clinical Director of Genitourinary Malignancies, Division of Oncology, Department of Internal Medicine Washington, University in St. Louis Saint
Louis, MO

​​Charles Ryan, MD
President and CEO Prostate Cancer Foundation

Sarmad Sadeghi, MD, PhD
Associate Professor of Clinical Medicine and Urology Division of Medical Oncology USC Institute of Urology Keck USC School of Medicine
University of Southern California
Los Angeles, CA 

Amirali Salmasi, MD
Associate Professor, Department of Urology
Urologic Oncology UC San Diego Health
San Diego, CA

John Sarantopoulos, MD
Associate Professor Peggy & Lowry Mays
Distinguished Chair, Hematology Oncology UT Health San Antonio
San Antonio, TX

​​A. Oliver Sartor, MD
Director Radiopharmaceutical Trials
Mayo Clinic
Minnesota, FL

Kerry Schaffer, MD
Assistant Professor,  Department of Medicine Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, TN

​​​​​​Laura Anne Sena, MD, PhD
Assistant Professor of Oncology
Johns Hopkins University
Baltimore, MD

​​Samer A. Srour, MB ChB, MS
Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center Houston, TX

Walter Stadler, MD, FACP
Fred C. Buffett Professor, Depts of Medicine & Surgery Dean for Clinical Research, Senior Advisor to the Director, Comprehensive Cancer Center
UChicago Medicine 
Chicago, IL

​​​Cora N. Sternberg, MD
Clinical Director, Englander Institute for Precision Medicine, Professor of Medicine, Sandra and
Edward Meyer Cancer Center
Weill Cornell Medicine
New York, NY

​​​Tyler F. Stewart, MD
 Assistant Professor Medical Oncology, University of California, San Diego
La Jolla, CA

​​​Russell Szmulewitz, MD
Associate Professor of Medicine Program Leader, Genitourinary Oncology Section of Hematology/Oncology, Dept. of Medicine,
The University of Chicago
Chicago, IL

​​​Nizar M. Tannir, MD, FACP
Professor Ransom Horne, Jr.
Professor for Cancer Research RMC Alliance,
Founder and President
Department of Genitourinary Medical Oncology Division of Cancer Medicine
UT MD Anderson Cancer Center
Houston, TX

Amy Taylor, MD
Fellow Physician Madison, WI
Houston, TX

Benjamin A. Teply, MD
Associate Professor, Division of Oncology & Hematology Fred and Pamela Buffett Cancer Center
University of Nebraska Medical Center
Omaha, NE 

​​​Hong Truong, MD
Assistant Professor
Penn State Health
Hershey, PA

​​Mark Tyson, II, MD, MPH
Urologist Oncologist
Mayo Clinic
Phoenix, AZ

Samir Zaidi, MD, PhD
Louis V. Gerstner Jr. Physician Scholar Assistant Attending, Genitourinary Oncology Service Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center
New York, NY 

Kevin K. Zarrabi, MD
Assistant Professor, Thomas Jefferson University Philadelphia, PA   

Tian Zhang, MD, MHS
Associate Professor, Division of Hematology & Oncology Department of Internal Medicine
UT Southwestern Medical Center,  Harold C. Simmons Comprehensive Cancer Center
Dallas, TX  

Alexandre R. Zlotta, MD, PhD
Professor and Howard Sokolowski
Chair in Uro-Oncological Research, Department of Surgery (Urology), University of Toronto, Director, Uro-Oncology, Mount Sinai Hospital, Associate Scientist,  Lunenfeld-Tanenbaum Research Institute, Staff, Division of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network
Toronto, Canada 

adyt

Piyush K. Agarwal, MD
Professor of Surgery and Urology, Director, Bladder Cancer Program Fellowship
Director, Urologic Oncology Comprehensive Cancer Research Center, The University of Chicago, Chicago, IL

Piyush K. Agarwal, MD, is a highly respected urologic surgeon who specializes in the multidisciplinary management of bladder cancer, using complex surgical techniques, such as robotic and open radical cystectomy and continent urinary diversions, to treat his patients. Along with bladder cancer, Dr. Agarwal is also an expert in all urologic cancers, including prostate, testicular and penile carcinoma. Dr. Agarwal’s clinical and laboratory research focuses primarily on bladder cancer, specifically BCG-unresponsive disease, the urinary microbiome, molecular targeted therapy and immunotherapy. He has conducted several original, investigator-initiated clinical trials and has presented his research at national and international meetings. Dr. Agarwal has served on the FDA’s oncologic drug advisory committee and has authored six book chapters and over 90 manuscripts. In addition to his clinical and research work, Dr. Agarwal is also committed to teaching. He is an associate editor for two medical journals with a focus in urothelial cancers and has mentored over 50 trainees at various levels to successful careers in academic medicine.

w

Hamed Ahmadi, MD
Assistant Professor University of Minnesota, Minneapolis, MN

Dr Hamed Ahmadi is an Assistant Professor at University of Minnesota. He attended Tehran University of Medical Sciences for medical school and then completed his residency training in Urologic surgery at Oregon Health and Science University in Portland, Oregon. He recently completed Society of Urologic Oncology fellowship at University of Southern California and joined our department shortly after. He is specialized in open and minimally invasive management of complex genitourinary cancers. His main research interest is tumor marker-based management of bladder and testis cancer.

p3

Omar Alhalabi, MD
Assistant Professor Department of Genitourinary Medical Oncology Division of Cancer Medicine,  UT MD Anderson Cancer Center,  Houston, TX

After graduating medical school in Syria, scientific research seemed impossible and out of reach. Eight years later, he was very fortunate to have joined the faculty at MD Anderson as a clinical investigator in July 2020 and to have developed the following research interests: 1) Defining the genomic and metabolic drivers of resistance to immunotherapy in bladder cancer. 2) Developing the urine metabolome as an accessible biomarker reflective of bladder cancer immunity. 3) Developing effective novel therapies guided by understanding the biology of bladder cancer. His first funded grant was in 2019, when he received the Young Investigator Award (YIA) from the American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation (CCF) for the investigation of triple-agent combination therapy with pemetrexed, adenosine inhibitor, and anti-PD-L1 in methylthioadenosine phosphorylase (MTAP) deficient bladder cancer. This award had a significant impact on me as a researcher and allowed to witness the transition of bench findings to patients and vice versa. He became interested in studying MTAP deficiency in 9p21-loss bladder cancer because those patients (consist 25% of bladder cancer population) have significantly poorer prognosis (Alhalabi et al. European Urology Oncology, 2021) Furthermore, his group’s work (Han et al. Nature Communications, 2022) has shown that loss of 9p21 confers a cold tumor immune microenvironment (TIME) and primary resistance to immunotherapy. Therefore, he has been exploring the therapeutic vulnerabilities created by MTAP loss. His YIA project showed that MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers (Alhalabi et al. Nature Communications, 2022). Using these findings, his team has launched an investigator-initiated clinical trial (NCT05335941) using the triplet combination of antifolates, antiadenosine and antiPD1 against MTAP deficient bladder cancer. In this P01 application, he will co-lead project 3 and aim to test the hypothesis that pemetrexed plus anti-PD-(L)1 + adenosine 2A/B receptor inhibitor combination therapy will effectively modulate the TIME to favor killing of 9p21-loss bladder cancer.

p_28

​​Gustavo Ayala, MD
Professor Vice Chair, Outreach Department of Pathology and Laboratory Medicine, UT Health Houston, Houston, TX

Dr. Gustavo Ayala, Director of the UT*Path Urologic Pathology Division, is a highly experienced nationally and internationally recognized urologic pathologist. After training at the National Cancer Institute in Paraguay, Dr. Ayala completed his residency at Georgetown University and a fellowship at Yale University School of Medicine. After 3 years at the Hahnemann Hospital in Philadelphia he joined the faculty at Baylor College of Medicine as an Assistant Professor. In a short period of time, he rose through the ranks to become a tenured Professor of Pathology and Scott Department of Urology. While at Baylor, he was awarder the R. Clarence and Irene H. Fulbright Endowed Chair, which he held until he left BCM late in 2011. Dr. Ayala has a very active basic science, clinical and translational research for which he received uninterrupted funding from the National Cancer Institute, The Prostate Cancer Foundation, the Department of Defense and other foundation and industry grants. Dr. Ayala is a recognized leader in urologic cancer research and an innovator in the field. He has published more than 120 scholarly manuscripts. His prostate cancer biomarkers development effort, funded by the National Cancer Institute, has derived into new models of prediction for prostate cancer based on the interaction between cancer and host. He is a member of several professional organizations including the College of American Pathologists, the Arthur Purdy Stout Society, the International Urologic Pathology Society and the Texas Society of Pathology, where he serves as a board member. He served as a reviewer for many pathology, and oncology journals, and served on national and international grant review committees and expert panels. Dr. Ayala’s work has been highlighted in the journal Nature.

w2

Mark W. Ball, MD
Associate Research Physician Urologic Oncology Branch Associate Director, Urologic Oncology Fellowship National Cancer Institute, Bethesda, MD

Dr. Ball is a fellowship-trained urologic oncologic surgeon. He received his undergraduate degree in biochemistry and molecular biology from Centre College, graduating magna cum laude and Phi Beta Kappa. He received his M.D. from the Johns Hopkins University School of Medicine. He completed his internship and residency at the James Buchanan Brady Urological Institute at Johns Hopkins. He subsequently completed a Society of Urologic Oncology-accredited fellowship at the National Cancer Institute where he worked in the laboratory of W. Marston Linehan, M.D. He is board-certified by the American Board of Urology. Dr. Mark Ball is an attending surgeon in the Urologic Oncology Branch of the National Cancer Institute and Associate Program Director of the Urologic Oncology Fellowship Program. He is the highest volume robotic kidney surgeon in the metropolitan Washington D.C. area and an internationally recognized expert in kidney cancer. He specializes in the surgical treatment of kidney and adrenal tumors and performs robotic, laparoscopic and open surgery. He has particular expertise in robotic partial nephrectomy and robotic partial adrenalectomy for hereditary kidney cancer syndromes, and has removed over 1,000 kidney tumors during partial nephrectomy procedures. He is experienced in reoperative surgery in patients with a history of prior surgeries and in patients with multiple tumors. He has authored over 115 manuscripts and regularly presents at national and international conferences. Dr. Ball has been the recipient of several academic honors including election to the Alpha Omega Alpha honor society, outstanding laparoscopic surgeon from the Society of Laparoendoscopic Surgery, outstanding research from the Society of Urologic Oncology, recipient of a competitive LRP award from the NIH, and multiple teaching awards.

p33

Arnab Basu, MD
Chief, Genitourinary Oncology, UAB O’Neal Comprehensive Cancer Center,  Interim Chief, Genitourinary Oncology, UAB O’Neal Comprehensive Cancer Center Assistant Professor, Genitourinary Oncology, UAB O’Neal Comprehensive Cancer Center Associate Scientist, UAB O’Neal Comprehensive Cancer Center, Birmingham, AL

Dr. Arnab Basu is an academic genitourinary oncologist focusing in the care of patients with Kidney Cancer & Bladder Cancer. Dr. Basu originally obtained his medical degree from the Medical College, Kolkata, the oldest medical school in Asia. He then completed a fellowship at the Indian Council of Medical Research and a Masters in Epidemiology and Biostatistical Methods in Clinical Research from the Johns Hopkins University in Baltimore , Maryland. He then completed his Internal Medicine training at the Johns Hopkins University & Sinai Hospital of Baltimore program. Dr. Basu also has fellowship training from the University of Southern California and the Cleveland Clinic Foundation where he focused on the care of patients with genitourinary malignancies Following his Training , Dr. Basu has joined UAB as a Associate Scientist with the Comprehensive Cancer Center and a Tenure Track Assistant Professor at the UAB School of Medicine. He holds a Alabama Drug Discovery Alliance award for the development of novel therapeutics for Kidney Cancer. Dr. Basu also has published on the role of circulating DNA analysis for the early detection and management of disease. Dr. Basu is experienced in the use of immunotherapy and targeted therapies in these diseases and has performed research in resistance mechanisms to immunotherapy. Dr. Basu is developing translational research programs in the genitourinary malignancies at UAB. In addition to kidney and bladder cancer , he also specializes in testicular, adrenal and prostate cancers.

p34

David J. Benjamin, MD
Medical Oncologist, Hoag Family Cancer Institute, Newport Beach, CA

Dr. David J. Benjamin is a genitourinary medical oncologist at Hoag Family Cancer Institute (Newport Beach, CA). He has co-authored over 50 publications in journals such as JAMA Oncology and Nature Reviews Urology. He received the 2022 Genitourinary Cancers Symposium Merit Award from Conquer Cancer, the ASCO Foundation, and received the 2022 UCI School of Medicine Outstanding Fellow/Resident Research Award for excellence in clinical/translational research.

Bilen

​​Mehmet Bilen, MD​
Associate Professor, Department of Hematology and Medical Oncology​, Emory University School of Medicine​, Director, Genitourinary Medical Oncology Program​, Winship Cancer Institute of Emory University​, Atlanta, GA

Mehmet Asim Bilen, MD, is an Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A board certified medical oncologist. Dr. Bilen is actively involved in clinical research and patient care in the area of genitourinary cancers. He serves as director of the Genitourinary Medical Oncology Program at Winship Cancer Institute of Emory University. He works closely with the Fellowship Program of the Department of Hematology and Medical Oncology by educating fellows on genitourinary oncology. He also serves on the Winship Clinical and Translational Review Committee.​ ​ Dr. Bilen is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He holds professional memberships with American Association for Cancer Research and American Society of Clinical Oncology.

p35

Jacqueline T. Brown, MD
Assistant Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, Genitourinary Oncologist Winship Cancer Institute of Emory University Atlanta, GA

Dr. Jacqueline T. Brown is an Assistant Professor at the Emory University School of Medicine and specializes in the management of genitourinary malignancies at the Winship Cancer Institute of Emory University. She is actively involved in clinical trials in genitourinary cancers and the Phase I clinical trials unit at Winship. She is interested in improving clinical outcomes for older patients with bladder and prostate cancer and is passionate about improving oncology medical education at Emory and beyond.

w3

Manojkumar Bupathi, MD, MS
Medical Oncologist Rocky Mountain Cancer Centers Executive Co-Chair GU Research- Sarah Cannon Research Institute,  Aurora, CO

Dr. Bupathi is a board-certified medical oncologist and joined Rocky Mountain Cancer Centers in 2017. He specializes in solid tumors with an advanced subspecialty expertise in breast cancers and genitourinary cancers (adrenal, bladder, kidney, penile, prostate, and testicular). He attended medical school at St Georges University, School of Medicine, Grenada, WI, followed by residency at Case Western Reserve University, in Cleveland, OH. He completed an Investigational Cancer Therapeutics Fellowship, at the University of Texas, MD Anderson Cancer Center, in Houston, a Medical Oncology Fellowship, at the Ohio State University, in Columbus, OH, a Gastrointestinal Oncology Advanced Fellowship, at the Ohio State University, in Columbus, OH, and a Research Fellowship, at the Cleveland Clinic Foundation, Department of Translational Hematology & Oncology, in Cleveland, OH. He participates in many tumor boards, where he collaborates with other cancer specialists including surgeons, radiologists, pathologists, and radiation oncologists. This allows him to provide a comprehensive, multi-disciplinary approach to cancer treatment recommendations such as chemotherapy, targeted therapies, and immunotherapies. Dr. Bupathi has a strong interest in the field of personalized medicine and how genomics and molecular pathways impact cancer treatment options. Dr. Bupathi is the Co-Chair for the US Oncology Genitourinary Cancer Research Program and serves as principal investigator for many Phase 1, Phase II, and Phase III studies. He emphasizes the importance of participating in clinical research trials whenever possible to ensu

p_72

Maria Carlo, MD
Assistant Attending Physician, Memorial Sloan Kettering Cancer Center, New York, NY

Dr. Maria Carlo is an Assistant Attending Physician in Memorial Sloan Kettering Cancer Center. She earned her medical degree from Harvard Medical School, completed her residency in Internal Medicine from Brigham and Women’s Hospital, andfellowship in Hematology and Oncology from Memorial Sloan Kettering Cancer Center. She is a medical oncologist who specializes in caring for people with advanced kidney cancer. She also provide clinical counseling and genetic testing for people who may have an inherited predisposition to genitourinary cancers, such as kidney and prostate cancers, and other cancers.

chwala

Sant P. Chawla, MD
Director,  Sarcoma Oncology Center,  Santa Monica, CA

Sant P. Chawla, M.D., is director of the Cancer Center of Southern California in Santa Monica, California, a comprehensive cancer treatment and clinical research facility. Sant P. Chawla, M.D. holds medical licensures in both Texas and California, and he is board certified in Internal Medicine and Medical Oncology. He is a pioneering physician whose work in sarcoma oncology has brought him several accolades and recognition as one of the world’s leading authorities in medical treatment and clinical research for bone and soft-tissue sarcomas and sarcoma therapy. Dr. Chawla heads the Sarcoma Oncology Center in Santa Monica, CA where he leads clinical cancer research efforts and conducted groundbreaking clinical research in pancreatic carcinoma, gynecologic tumors, breast cancer, glioblastoma, malignant peripheral nerve sheath tumors, lung cancer and gastrointestinal tumors. Dr. Chawla received his medical degree and completed his residency training in Internal Medicine at the All India Institute of Medical Sciences in New Delhi. From there, he went on to the Auckland Hospital in Auckland, New Zealand to begin his specialty training in medical oncology. He also completed his fellowship in medical oncology in New Zealand, at the Fellow Royal Australasian College of Physicians (F.R.A.C.P.). Dr. Chawla’s pioneering work in cancer research began in the 1980s when he contributed to breakthroughs in the treatment of young patients with osteosarcoma. He innovated limb-saving treatment for these young patients where amputation was previously the only option. Since that time, he has conducted over 60 clinical trials for cancer drugs now approved by the FDA and EMA, including carboplatin, trabectedin (Yondalis), pazopanib, eribulin, aprepitant and denosumab. Most recently, the Center completed a breakthrough Phase II trial for Aldoxorubicin (second line for soft tissue sarcomas).

adyt2

Jonathan Chou, MD, PhD
Assistant Professor of Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA

Dr Jonathan Chou is a physician-scientist in the Division of Hematology/Oncology and an attending physician in the Genitourinary Medical Oncology Clinic at UCSF. Dr Chou earned his medical degree and a doctorate in biomedical sciences from UCSF. He also completed a residency in internal medicine and a fellowship in oncology at UCSF. Dr. Jonathan Chou cares for patients with cancers affecting the genital and urinary organs, including prostate, bladder, kidney and testicular cancers. His areas of research include developing more precise ways to treat cancer. He studies molecular subtypes of cancer and uses genome-editing technology to engineer cell models in the lab, seeking to understand how specific mutations affect cancer properties. He also uses genetic and drug screening to find new ways of killing cancer cells, and incorporates patient-derived tumor xenografts (models in which cells from a patient’s tumor are implanted in an animal) to investigate drug resistance.

pictures2

Matthew Dallos, MD
Genitourinary Oncologist, Assistant Attending Physician, Department of Medicine, Solid Tumor Genito-Urinary Service, Memorial Sloan Kettering Cancer Center, New York, NY

Dr. Matthew Dallos is a medical oncologist and Assistant Professor of Medicine at Columbia University Medical Center who specializes in the treatment of prostate cancer. Dr. Dallos received his bachelor’s degree in neuroscience from Brown University. He earned his MD with distinction in research from Northwestern University where he was also a HHMI Research Scholar. He completed his internship and resident at NYU followed by medical oncology fellowship at Columbia University. He has received numerous awards including an ASCO Young Investigator Award, PCF Young Investigator Award and PCF/Movember Challenge Award. Dr Dallos is an expert in prostate cancer immunotherapy and his research focuses on harnessing the immune system for the treatment of both localized and metastatic disease. He previously discovered several key mechanisms in which androgen deprivation therapy (ADT) modulates the immune system. These findings are now being translated into a number of ongoing innovative clinical trials that he leads as principle investigator. His ultimate goal is to improve both the quality of life and the chance for cure for men living with prostate cancer.

p36

Siamak Daneshmand, MD
Professor of Urology and Medicine (Oncology) -Clinical Scholar Director of Urologic Oncology Director of Clinical Research Urologic Oncology Fellowship Director USC/Norris Comprehensive Cancer Center

Dr. Sia Daneshmand is currently Professor of Urology and Medicine (Oncology) with Clinical Scholar designation and serves as director of urologic oncology, as well as the urologic oncology (SUO) fellowship director at the University of Southern California (USC) in Los Angeles. His main clinical interests include bladder cancer, testicular cancer, and advanced kidney cancer. He is a leading authority in the management of complex germ cell tumors and nerve-sparing retroperitoneal lymph node dissection (RPLND) following chemotherapy for advanced testicular cancer and is one of the highest volume surgeons for this disease in the country. His main research interests focus on the use of pathways to improve peri-operative outcomes following radical cystectomy and post-chemo RPLND, use of serum and molecular markers and new technologies in diagnosis and management of bladder and testicular cancers, as well as functional outcomes following orthotopic urinary diversion. He serves on the AUA Guidelines panel for non-muscle invasive bladder cancer, as well as the AUA Guidelines panel for Testicular cancer. He currently serves as the chair of bladder section of the SUO Clinical Trials Consortium (SUO-CTC), is on the scientific steering committee of several bladder cancer clinical trials and has led over a dozen clinical trials in bladder cancer and a pivotal trial in testicular cancer (SEMS). He was recently appointed. He is current secretary of the Western Section of the AUA. He is a member of Alpha Omega Alpha medical honor society and has been designated one of the “America’s Top Cancer Doctors” for the past 12 consecutive years. He has been a career leader in academic investigations in bladder cancer and germ cell tumors and was recently appointed as the chair of the SWOG local bladder committee. He has been a visiting professor at more than 25 institutions around the world. He has presented over 500 abstracts at scientific meetings and has authored over 375 peer-reviewed articles, reviews, and book chapters.

p37

David Einstein, MD
Assistant Professor of Medicine, Beth Israel Deaconess Medical Center, Boston MA

Dr. Einstein is an academic medical oncologist specializing in genitourinary (GU) cancers. He care for patients with prostate, bladder, kidney, and testicular cancer. He spend approximately half of my time on genitourinary oncology research, particularly focusing on immunotherapy and targeted approaches in prostate, bladder, and kidney cancers, with support from the Prostate Cancer Foundation, NIH, DoD, BIDMC, and industry partners. He is interested in clinical trial development, serving as overall Principal Investigator (PI) and site PI of several Dana-Farber/Harvard Cancer Center (DF/HCC) clinical trials that investigate immune-based, targeted, and radioligand therapies for GU cancers. In addition, he is the Director of GU Oncology Clinical Research for the Beth Israel-Lahey Health network and PI of the DF/HCC GU Rapid Autopsy program, a component of the Pathology core of the DF/HCC Prostate SPORE. He is passionate about teaching: He is a two-time author of the American Society of Clinical Oncology Self-Evaluation Program GU chapter and a two-time winner of the annual teaching award from our fellowship program. Finally, he has developed tools to improve quality of life, physician communication, and end-of-life decision-making, especially as it relates to patients with GU cancers, and to promote patient wellbeing outside of my clinic, He serves as medical advisor to the Boston Prostate Cancer Support Group and the Massachusetts Prostate Cancer Coalition.

w5

Scott Eggener, MD
Bruce and Beth White Family Professor of Surgery Vice Chair, Section of Urology Director, High Risk and Advanced Prostate Cancer Clinic The University of Chicago, Chicago, IL

Scott Eggener, MD, is a urologic oncologist experienced in robotic and open surgeon who specializes in the care of patients with prostate, kidney and testicular cancers. Dr. Eggener is co-director of the UChicago Medicine High-Risk and Advanced Prostate Cancer Clinic (UCHAP), a program that provides focused care for men at high risk for prostate cancer and those with advanced disease. His research — which has resulted in over 250 publications — exclusively focuses on urologic cancers and primarily focuses on improving the screening, imaging and treatment of men with prostate cancer. Dr. Eggener's research has been presented at national and international meetings. He is a senior faculty scholar at the Bucksbaum Institute for Clinical Excellence, an associate editor at four medical journals, on the executive board of International Volunteers in Urology and has chaired or participated in multiple ASCO/AUA cancer guideline panels.

p38

Hamid Emamekhoo, MD
Associate Professor of Medicine, Division of Hematology and Medical Oncology, Director of Clinical Cancer Research, Informatics University of Wisconsin, Carbone Cancer Center, Madison, WI

Dr. Hamid Emamekhoo is an Associate Professor in the Division of Hematology, Medical Oncology and Palliative Care and Director of Clinical Cancer Research Informatics at University of Wisconsin Carbone Cancer Center . He is a medical oncologist with clinical and research focus on genitourinary malignancies. He received his medical degree from Shahid Beheshti University of Medical Sciences, Tehran, residency in Internal medicine from Good Samaritan Hospital and fellowship in Hematology and Oncology from Cleveland Clinic. His previous research in gene targeting has evolved into an interest in a personalized approach to cancer treatment and precision oncology. He focuses on immunotherapy innovations in cancer treatment and currently serves as the principal investigator, or co-investigator, on multiple ongoing clinical trials using immunotherapy and targeted therapies in different stages of kidney, bladder and prostate cancer at UW-Madison. Dr. Emamekhoo is a member of the American Association of Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).

pictures5

Benjamin Garmezy, MD
Associate Director, Genitourinary Research Program, Co-Chair, GU Executive Committee, SCRI Network, Sarah Cannon Research Institute, GU Medical Oncologist and Investigator SCRI Oncology Partners, Nashville, TN

Dr. Benjamin Garmezy, M.D., is a board-certified medical oncologist and the Associate Director of Genitourinary Research for Sarah Cannon Research Institute at Tennessee Oncology. Dr. Garmezy specializes in genitourinary (GU) oncology research. He oversees investigational therapy trials for prostate, kidney, bladder and testicular cancers and offers a variety of treatment options to patients, including chemotherapy, immunotherapy, targeted therapy and precision oncology. Dr. Garmezy received his undergraduate degree from Amherst College and his Doctorate of Medicine from Baylor College of Medicine. Prior to joining SCRI, he completed his internal medicine residency at the University of Michigan and his fellowship in hematology/oncology at The University of Texas MD Anderson Cancer Center.

p_84

​​Giannicola Genovese, MD, PhD
Associate Professor​, Department of Genitourinary Medical Oncology - Research​, Division of Cancer Medicine,​ UT MD Anderson Cancer Center, ​ Houston, TX

Dr. Giannicola Genovese is an Associate Professor in the Department of Genitourinary Medical Oncology at UT MD Anderson Cancer Center. He earned his medical degree from University of Rome, PhD from Catholic University of Sacred Heart, Rome. He completed his Clinical Fellowship in Internal Medicine/Oncology from Catholic University of Rome. His research program aims to develop cutting-edge tools to elucidate tumor plasticity and to characterize the functional drivers that underlie treatment resistance. Overall, he conducts research in a manner that produces results with immediate translational potential. While his laboratory focuses on renal and pancreatic malignancies, students are encouraged to consider building hypotheses that address the challenges with treating all solid tumors.

pictures6

Saby George, MD, FACP
Professor of Oncology, Director of Network Clinical Trials, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

Dr. Saby George is a Professor of Oncology and Director of Network Clinical Trials in Department of Medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York. He received his medical degree from Kottayam Medical College, Kerala, India and completed his residency from Wright State University, Dayton, Ohio. Dr George completed his fellowship in Experimental therapeutics from Cleveland Clinic Taussig Cancer Institute, Cleveland and in Medical Oncology from University of Texas Health Sciences Center at San Antonio, San Antonio. Dr. George research interests lies in Kidney cancer: clinical trials, novel drug development, mechanism of resistance formation to tyrosine kinase inhibitors, improving the response evaluation criteria and development of biomarkers. Prostate cancer: Castrate refractory prostate cancer, high Gleason score disease, improving androgen deprivation therapy and biomarker development. He also serves as a principal investigator of Phase III PROBE trial- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer and for other trial in Phase I/II— Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer.

w6

Julie Graff, MD
Staff Oncologist, VA Portland Health Care System Director of PATCH (Prostate cancer Analysis for Therapy CHoice) Professor, Hematology & Medical Oncology OHSU Knight Cancer Institute Portland, OR

Dr. Graff was born and raised in Phoenix, Arizona. She attended University of Arizona and graduated with a BS in Applied Mathematics with honors in 1998. She then went to medical school at George Washington University where she received her MD with distinction in 2003. She moved to Portland, OR, and completed residency and fellowship at the Oregon Health & Science University in 2009. Since that time, she has been on the faculty at the Knight Cancer Institute OHSU and on the staff at VA Portland Health Care System, where she has been the chief of hematology/oncology since 2018. Dr. Graff focuses on helping patients with cancer live well. She sees patients with genitourinary cancers, such as prostate, kidney, bladder and testicular cancers, but her research is on prostate cancer. She has designed and implemented many clinical trials that have resulted in some dramatic results. She became internationally recognized for her work in immunotherapy in prostate cancer (link). This work has spun off into multiple trials. In 2018, she earned a prestigious $1M Movember Challenge Award from the Prostate Cancer Foundation to study the effect of manipulation of the gut microbiota on responses to immunotherapy in Veterans with advanced prostate cancer.

a

Scott Haake, MD, PhD
Assistant Professor, Division of Hematology & Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN

As a kidney cancer-focused investigator, Dr Haake leads a research team focused on the study of basic mechanisms of kidney cancer development and progression and seek to actively translate this knowledge into interventions that improve the lives of kidney cancer patients. For example, they have a DOD-funded project that seeks to develop RNAseq-based biomarkers that match approved first-line therapies to the unique biology of an individual patient’s tumor, thus testing the hypothesis that this tailored therapy will result in superior clinical outcomes. In addition, they have a new study that will seek to translate this tissue-based biomarker into a liquid-based biomarker that utilizes RNA sequencing of circulating tumor cells to assign tumor to these predictive clusters. Other DOD funding seeks to train artificial intelligence to correlate spatial patterns derived from multiplex immunofluorescence in papillary renal cellc carcinoma tissues with clinical outcomes. The focus of his NCI K08 award is to study the role of extracellular matrix (ECM) and integrin signaling in cancer. He demonstrated that cancer cells exhibit constitutive, ligand-independent activation of ECM receptors, and this signaling is required for tumor initiation. His research has been published in peer-reviewed journals including Cell, The New England Journal of Medicine, Cancer Cell, Cancer, Clinical Cancer Research, and others. As a board-certified medical oncologist, he cares for patients at both Vanderbilt University Medical Center and the Nashville VA Hospital.

p_2

Michael C. Haffner, MD, PhD
Assistant Professor, Pathology Human Biology Division Clinical Research Division Fred Hutchinson Cancer Center Assistant Professor, Pathology, University of Washington School of Medicine, Seattle, WA

Dr. Michael Haffner is a physician-scientist who specializes in genitourinary cancers. As a pathologist, he diagnoses patients’ tumors. As a research scientist, he studies the cellular changes that allow tumor cells, particularly prostate tumor cells, to metastasize, or spread through the body. Dr. Haffner focuses on the cytoskeleton, the protein network that gives cells their shape and size and is involved in nearly every cellular process, from division to movement. The shape and size of cancer cells often differs from normal cells and these changes may be due to changes in how cells build and organize their cytoskeletons. But how cytoskeletal changes may promote tumor progression, including metastasis, remain unclear. Through understanding the connection between the cytoskeleton and cancer, Dr. Haffner aims to identify new targets for future therapies designed to halt advanced prostate cancer.

pictures7

Raquibul Hannan, MD, PhD
Professor, Radiation Oncology, Urology and Immunology, Chief, Genitourinary Radiation Oncology, UT Southwestern Medical Center, Dallas, TX

Dr. Raquibul Hannan, Professor and Chief of Genitourinary Radiation Oncology Service, became fascinated with cancer as an undergraduate at New York University. His curiosity led him to pursue a combined medical degree and Ph.D. at State University of New York at Brooklyn from 1999 to 2006. For his Ph.D. research he worked on the immunology of pancreatic carcinogenesis and discovered a novel marker for pancreatic cancer. Following a medical internship the next year, he completed his residency in radiation oncology at Montefiore Medical Center and Albert Einstein College of Medicine in 2011. At UT Southwestern Medical Center, Dr. Hannan specializes in radiation treatment of genitourinary (GU) cancers including prostate, kidney, bladder, penile, testicular, and ureteral cancer. Dr. Hannan is knowledgeable in a range of radiation techniques including IMRT, IGRT, linac-based SRS, SBRT, and intracavitary and interstitial brachytherapy. As an expert in these areas as well as a leading young researcher on the topic of immunologic effects of radiation treatment and immunotherapy in general, he holds two international patents and has presented his findings at symposiums and conferences around the world. Dr. Hannan is a member of a number of professional organizations including the American Society of Radiation Oncology (ASTRO), the American Board of Radiology (ABR), the American College of Radiology (ACR), the Radiological Society of North America (RSNA), and the American Society of Clinical Oncology (ASCO).

p310

​​Michael R. Harrison, MD
Associate Professor of Medicine, Member of the Duke Cancer Institute, Duke University Durham, NC

​Dr. Michael Harrison is an Associate Professor in Duke University. He earned his medical degree from Tulane University School of Medicine, residency in Internal Medicine from Tulane University and fellowship in Medical Oncology from University of Wisconsin. He specialize in treating people with genitourinary (GU) cancers, such as bladder, prostate, testicular and kidney cancer.  

adyt3

Jim C. Hu, MD, MPH
Ronald P. Lynch, Professor of Urologic Oncology, Professor of Urology, Weill Cornell Medicine New York, NY

Dr. Jim Hu is a urologic oncologist with his undergraduate degree in Economics, his Master’s in Public Health in Health Policy and Management from Johns Hopkins University, and his Medical Degree from Baylor College of Medicine. He completed his Urology Residency at the David Geffen School of Medicine at UCLA and his Robotic Surgery/Urologic Oncology Fellowship in 2004 at City of Hope National Medical Center. He began his career as the Director of Robotic and Minimally Invasive Surgery at Brigham and Women's Hospital and Instructor at Harvard Medical School and was quickly promoted to Director of the Prostate Cancer Program at Dana Farber/Harvard Cancer Center and Associate Professor. He was then recruited back to the David Geffen School of Medicine at UCLA as the Henry Singleton Chair of Robotic and Minimally Invasive Surgery, where he led the minimally invasive prostate cancer, kidney cancer, and kidney donor nephrectomy programs. He was promoted to Professor before joining the faculty at Weill Cornell Medical College in 2015 as the Director of the LeFrak Center for Robotic Surgery and the Ronald P. Lynch Chair in Urologic Oncology. He currently serves as the Vice-Chair of Clinical Research, Chair of Quality and Patient Safety, and the Course Director for Urology Grand Rounds. Dr. Hu is an internationally renowned surgical innovator and health services researcher. His comparative effectiveness research interests have been funded by the Department of Defense, the National Cancer Institute, and the Livestrong Foundation. He is currently the contact principal investigator on two National Cancer Institute R0-1 randomized clinical trials investigating novel, potentially practice-changing approaches to prostate biopsy and radical prostatectomy. He is also the contact principal investigator on two Patient-Centered Outcomes Research Institute (PCORI) awards investigating prostate biopsy and comparative effectiveness of focal therapy, stereotactic body radiation therapy vs. conventional prostate cancer therapies. He has been awarded more than $12 million in peer-reviewed funding, and he has authored more than 300 peer-reviewed papers. His discoveries have been published in the most prestigious and exclusive medical journals, such as the New England Journal of Medicine, the Journal of the American Medical Association, and the Journal of Clinical Oncology, as well as featured in the New York Times, Wall Street Journal, and Boston Globe. In addition, Dr. Hu has published the most advances/videos of technical modifications internationally in European Urology Surgery in Motion to improve prostate and kidney cancer surgical outcomes. Dr. Hu has performed over 4000 laparoscopic, robotic and open procedures.

pictures8

Eric Jonasch, MD
Professor Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dr. Jonasch is Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Center at the University of Texas M. D. Anderson Cancer Center in Houston, Texas. He is director of the VHL Clinical Center at the MD Anderson Cancer Center, co-Director of the MD Anderson Kidney Cancer Research Program, and performs clinical, translational and basic research in kidney carcinoma and VHL disease.  Dr. Jonasch has authored over 190 articles published in peer-reviewed journals and is editor of the textbook: Kidney Cancer, Principles and Practice. Dr. Jonasch has a long history of service in the kidney cancer community. He serves as Vice-Chair of the NCCN Kidney Cancer Guideline Panel, is a member of the U.S. NCI Renal Task Force and is a Board member of the VHL Alliance.

p_29

Joseph W. Kim, MD
Associate Professor of Medicine (Medical Oncology), Yale School of Medicine Director of Prostate Cancer Research for GU DART, Yale Cancer Center New Haven, CT

Dr. Joseph Kim is a board-certified medical oncologist and a Director of the Prostate Cancer Research Program for Prostate and Urological Cancers DART of Yale Cancer Center. He is a recipient of the Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI) and a recipient of other awards from Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). Dr. Kim has led several peer-reviewed, NCI-sponsored, investigator-initiated clinical trials in prostate cancer, bladder cancer, and other solid tumors as a study chair. Dr. Joseph Kim serves as an author/editor of the genitourinary (GU) cancers chapter of ASCO-SEP, an educational textbook for medical oncologists, and a co-editor of the GU cancers section of a peer-reviewed journal, Current Oncology Report, and ad hoc reviewer of multiple oncology journals. He has been invited as a speaker for numerous international and national academic conferences including GU Cancers Symposium, ASCO Annual Meeting, CTEP/ NCI meeting, ASCO Direct highlights, International Genitourinary Cancer Conference, and many others. His passion lies in delivering compassionate, patient-centered, and evidence-based care for patients with genitourinary cancer including prostate cancer, bladder, and other urinary tract cancer, testicular cancer, and penile cancer. He is also passionate about developing and executing hypothesis-driven clinical trials of novel therapies in GU cancers and other solid tumors.

Manish Kohli

Manish Kohli, MD
Professor, Division of Oncology, School of Medicine Jack R. and Hazel M. Robertson Presidential Endowed, Chair, Huntsman Cancer Institute, Salt Lake City, UT

As a Medical Oncologist, my primary focus is to deliver “convergence sciences”- based solutions to deliver precision medicine in cancer. I am actively involved in multiple NIH (five active) grants as a Multi-PI, conducting research that fuse ultra-sensitive bio-engineering technologies with omic-based devices to develop molecular evidence-based algorithms that may potentially tackle unanswered challenges of cancer medicine, regardless of the clinical context which may range from novel therapeutic molecule discovery to molecular biomarkers of standard drugs. This goal de facto recognizes the need to bring different sciences together and to dedicate a multi-disciplinary approach for providing individualized patient care in the field of cancer. At the same time, we recognize that this achievement has to be cost-effective, to which end I work, collaborate and publish with a team of health economics outcome researchers (HEOR) in cancer medicine. As advancements in biological sciences and computing have progressed rapidly our on-going multi-disciplinary team science grant projects determine novel approaches to develop in silico multi-omic, machine learning and augmented intelligence platforms and algorithms that can be included unto innovative clinical trial designs as well. In addition to enhancing academic sciences our multi-disciplinary teams strive to achieve entrepreneurial advancement that result in Intellectual Property-patents and licenses. Throughout my career I have held various roles from leading as Director of Personalized Medicine Institutes in several cancer centers to conducting individualized medicine clinical trials. I have obtained several patents in this domain. Presently, I hold the esteemed position of Professor (tenured on joining) in the Department of Medicine and the Jack Presidential Endowed Chair at the University of Utah-Huntsman Cancer Institute in cancer research. Additionally, I also serve on several University/Institutional committees that range from Faculty Innovation Committees to Tenure Review Committees to Molecular Pathology to institutional search committees.

www

Kristine Peregrino Lacuna, MD
Assistant Attending, Memorial Sloan Kettering Cancer Center, New York, NY

Dr. Kristine Lacuna is a medical oncologist and assistant attending at Memorial Sloan Kettering Cancer Center. Dr. Lacuna received her bachelor’s degree in biology from Barnard College of Columbia University. She earned her MD from the State University of New York at Buffalo. She completed her internship and residency at Weill Cornell Medicine. She completed her hematology and medical oncology fellowship at Columbia University Irving Medical Center where she received several awards including ASCO annual meeting merit awards and an ASCO Young Investigator Award. Dr. Lacuna’s research focuses on better understanding the tumor biology of advanced prostate cancer and developing novel non-AR directed therapies.

p312

Elaine Lam, MD
Professor of Medicine​ School of Medicine​, Department of Medicine​, Division of Medical Oncology,​ University of Colorado Anschutz Medical Campus​, Aurora, CO

Dr. Lam is a Professor in the Department of Medicine/Division of Medical Oncology at the University of Colorado School of Medicine, Anschutz Medical Campus. She is a GU medical oncologist and clinical researcher at the University of Colorado Cancer Center. Dr. Lam is the Cancer Research Medical Director at UCHealth Cancer Center at Highlands Ranch Hospital and directs the Medical Oncology Kidney Cancer Program at the University of Colorado Cancer Center. She is also a voting member of the National Comprehensive Cancer Network Kidney Cancer Panel. She has been involved with numerous phase 1, 2, and 3 clinical trials for patients with genitourinary cancers.

www2

Andrew T. Lenis, MD
Assistant Professor of Urology Department of Urology Columbia University Irving Medical Center, New York, NY

Andrew T. Lenis, MD MS is an Assistant Professor of Urology at Columbia University Irving Medical Center (CUIMC). He specializes in the treatment of patients with bladder, kidney, prostate, testis and penile cancers. Dr. Lenis joined CUIMC as a surgeon-scientist with an interest and specialization in urothelial cancer. In the laboratory, Dr. Lenis works and collaborates with Michael Shen, PhD who is an expert in bladder and prostate developmental and molecular biology, and a pioneer in bladder tumor organoids. Dr. Lenis’ research has been funded by the American Urological Association, the American Cancer Society, and the American Society for Clinical Oncology. Most recently he is funded by the Herbert Irving Comprehensive Cancer Center Clinical Trialist Early Career Development Scholars Award to support an investigator-initiated bench-to-bedside clinical trial in non-muscle invasive bladder cancer.

p_8

​​Seth Paul Lerner, MD, FACS
Professor of Urology, Beth and Dave Swalm, Chair in Urologic Oncology,  Director of Urologic Oncology,  Director of the Multidisciplinary Bladder Cancer Program, Baylor College of Medicine, Houston, TX

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of over190 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. He is the founding co-editor-in-chief of the Bladder Cancer journal. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, integrated genomic analysis of bladder and upper urinary tract cancers, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 26 years experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, founding and former co-chair of the NCI Bladder Cancer Task Force and current co-chair of the NCI CTEP Genitourinary Steering Committee, and he has co-chaired the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer for the past 7 years. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is an active member of the prestigious American Association of Genitourinary Surgeons and is listed routinely among “America’s Top Doctors” and “Best Doctors in America.

w8

Paul Lin, MD, PhD
Assistant Professor of Medicine UT MD Anderson Cancer Center, Houston, TX

Dr. Paul Lin is an Assistant Professor in The University of Texas MD Anderson Cancer Center. He received his medical degree from Case Western Reserve University, completed his residency from the same institute and his fellowship from MD Anderson Cancer Center.

w9

Charlene Mantia, MD
Lank Center for Genitourinary Oncology Center for Cancer Therapeutic Innovation Department of Medical Oncology Dana-Farber Cancer Institute, Boston, MA

Dr. Charlene Mantia is a medical oncologist at Dana-Farber Cancer Institute who specializes in the treatment of cancers arising from the genitourinary tract. Dr. Mantia received her undergraduate degree from Tufts University and her medical degree from Albany Medical College. She completed her internal medicine residency and hematology/oncology fellowship at Beth Israel Deaconess Medical Center. In addition to caring for patients, Dr. Mantia conducts clinical and translational research with the goal of improving patient survival outcomes and treatment-related side effects.

pictures9

Nataliya Mar, MD, HS
Associate Clinical Professor, Division of Hematology/Oncology, Department of Medicine, School of Medicine, Chao Family Comprehensive Cancer Center UCI Health,  Orange, CA

Dr. Nataliya Mar is a hematology/oncology physician and HS Associate Clinical Professor at the University of California Irvine. She earned her bachelor’s degree from New York University, College of Arts and Science. She received her medical degree from State University of New York Downstate Health Sciences, University College of Medicine. She completed her residency in Internal Medicine from Zucker School of Medicine at Hofstra/Northwell at Lenox Hill Hospital and fellowship in Hematology and Medical Oncology from University of Connecticut. Dr. Mar specializes in genitourinary malignancies including prostate, bladder, renal cell, testicular, and penile cancer. In addition to delivering patient care, she is involved in the design and execution of clinical trials at the UC Irvine National Cancer Institute-designated Comprehensive Cancer Center. She has also presented multiple abstracts at national meetings and authored publications in peer-reviewed journals.

pictures10

Vitaly Margulis, MD
Professor of Urology, Paul C. Peters, M.D., Chair in Urology, UT Southwestern Medical Center, Dallas, TX

Vitaly Margulis, M.D., Professor of Urology at UT Southwestern Medical Center, graduated with honors from the University of Texas at Austin and UT Southwestern Medical School. He trained in the highly competitive urology residency program at UT Southwestern and completed a fellowship in urologic oncology at the University of Texas MD Anderson Cancer Center in Houston, where he was previously a Clinical Specialist in Urologic Oncology. He joined the UT Southwestern faculty in 2009. An expert surgeon, Dr. Margulis uses minimally invasive techniques to treat patients with soft-tissue tumors and kidney, prostate, bladder, testicular, penile, and adrenal cancers. His research projects include clinical and lab research focused on the biology of kidney cancer, the genetic changes that occur and cause it to spread, and how to stop it. Dr. Margulis travels frequently to lecture on urologic care and procedures. He is a Fellow of the American College of Surgeons and a member of the Society of Urologic Oncology, Endourologic Society, American Urological Association, American Medical Association, Texas Medical Association, Texas Urologic Association, Dallas County Medical Society, and Harris County Medical Society. He has authored several book chapters and published research in a variety of medical journals, including the Journal of the National Cancer Institute, Journal of Clinical Oncology, Urologic Oncology, Clinical Cancer Research, Oncogene, Cancer, Cancer Epidemiology, Biomarkers and Prevention, Urology, Journal of Urology, and British Journal of Urology. He also serves as a reviewer for those publications. Dr. Margulis has been included in D Magazine’s Best Doctors list as well as Texas Monthly’s Super Doctors list.

p314

Catherine Handy Marshall, MD, MPH
Assistant Professor, Department of Oncology, Sidney Kimmel Cancer Comprehensive Cancer Center, Attending Physician, Oncology Johns Hopkins University, Baltimore, MD

Dr. Marshall is an Assistant Professor of Oncology at Johns Hopkins School of Medicine where she is a medical oncologist specializing in the care of men with advanced prostate cancer

adyt4

Hannah Dzimitrowicz McManus, MD
Assistant Professor of Medicine, Duke University School of Medicne, Durham, NC

Dr. Hannah McManus is a medical oncologist and Assistant Professor of Medicine at Duke Cancer Institute in Durham, North Carolina. She specializes in the diagnosis and treatment of people with genitourinary cancers. In addition to her work caring for patients, she is a clinical investigator focusing on clinical trials for patients with GU cancer and utilization of real-world data to understand patterns of care and outcomes for patients. She completed medical school at Yale University and internal medicine residency and hematology/oncology fellowship training at Duke University.

a2

Richard A. Miller, MD
CEO Corvus Pharmaceuticals Inc, Burlingame, CA

p9

Matthew I. Milowsky, MD, FASCO
The George Gabriel and Frances Gable Villere, Distinguished Professor of Medicine, Section Chief, Genitourinary Oncology, Vice Chief for Research & Education UNC Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, NC

Dr. Matthew I Milowsky, MD, serves as Professor of Medicine and Clinical Professor of Urology at the University of North Carolina (UNC) School of Medicine in Chapel Hill, North Carolina. Dr Milowsky also serves as Section Chief of the Genitourinary Oncology Service, and Co-Director of the Urologic Oncology Program at UNC Lineberger Comprehensive Cancer Center. He joined UNC to lead the Genitourinary Oncology Research program with a focus on translational science and clinical trials for patients with urologic cancers. He earned his medical degree from the State University of New York (SUNY) Downstate College of Medicine in Brooklyn, New York, and completed his medical residency at New England Medical Center-Tufts in Boston, and hematology/oncology fellowship at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City. Dr Milowsky has published extensively in peer-reviewed journals and written several chapters including serving as an author on the Genitourinary Cancers section and as Associate Editor for the ASCO Medical Oncology Self-Evaluation Program (ASCO SEP). He has received several honors and awards including an NIH Institutional Research Fellowship Award in Hematology and DOD Physician Research Training Award, amongst others.

pictures12

Alicia Morgans, MD, MPH
Medical Director, Survivorship Program, Dana-Farber Cancer Institute, Associate Professor of Medicine, Harvard Medical School, Boston, MA

Dr. Alicia Morgans is a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at Dana-Farber Cancer Institute. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the Prostate Cancer Foundation and the Department of Defense. She is a member of the advanced and localized prostate cancer treatment guidelines committee of the American Urologic Association, and is a member of the cardio-oncology committee of the American Heart Association. Since 2016, she has been President of the Medical Advisory Board for ZERO, a non-profit organization dedicated to supporting education and research funding for prostate cancer research.

w12

Mohit Narang, MD
MOH chairman for P and T committee Maryland Oncology Hematology, Columbia,MD

Dr. Narang is a board-certified medical oncologist and hematologist. His practice expertise includes blood cancers, such as leukemia, lymphoma, and multiple myeloma, as well as nonmalignant blood disorders such as anemia and coagulation abnormalities. He is also a general medical oncologist treating colorectal, lung, genitourinary, and gastrointestinal cancers. Adopting a collaborative approach to care, Dr. Narang is a member of breast and general, tumor boards, presenting and reviewing cases with a multi-disciplinary team of cancer specialists such as surgeons, radiologists, pathologists, and radiation oncologists. His commitment to advancing cutting-edge cancer treatment in the community is the hallmark of his practice. This joint effort ensures his patients are given the best option for treatment tailored to their specific diagnosis. He holds professional memberships with the American Society of Clinical Oncology, the American Society of Hematology, as well as the European Society of Medical Oncology and European society of hematology

www3

Hao G. Nguyen, MD, PhD
Associate Professor in Residence; Urologic Oncology Richard and Leilani Grinold Endowed Professorship in Urology UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Hao Nguyen, MD, PhD, is Associate Professor in Residence of Urologic Oncology and holds the Richard and Leilani Grinold Endowed Professorship in Urology at the University of California, San Francisco. Dr. Nguyen received his undergraduate training from UC Berkeley, where he earned a degree in molecular cell biology in 1999. He received the Dean Scholarship from Boston University School of Medicine to join their Department of Biochemistry and Molecular Medicine MD-PhD program. He was awarded first prize for his PhD dissertation work investigating the role of defective chromosome segregation underlying cancer initiation. In 2007, he concurrently earned an MD from the School of Medicine. He completed his General Surgery and Urologic Surgery training at the University of California, Davis, and subsequently continued at UCSF to complete a fellowship in Urologic Oncology. At the end of his fellowship, Dr. Nguyen was recruited to join the UCSF Department of Urology, specializing in Urologic Oncology. He is part of the multidisciplinary urologic oncology team of the UCSF Helen Diller Family Comprehensive Cancer Center, located at Mission Bay. Dr. Nguyen’s clinical interests include the early detection, diagnosis, and management of prostate cancer, kidney cancer, bladder cancer, and other genitourinary malignancies. He performs open, robotic, laparoscopic, and endoscopic surgeries. He is particularly interested in focal therapies to treat early-stage prostate cancer, MRI fusion biopsy, and using novel biomarkers and imaging technology in risk-stratifying prostate, renal, and bladder cancer. Dr. Nguyen has authored over 70 peer-reviewed scientific articles and book chapters. His primary research focus is in elucidating the adaptive response pathways that prostate cancer cells use to evade cell death upon acquiring oncogenic lesions/stresses or even when they are under the selective pressure of chemotherapy or radiotherapy. He has been awarded the prestigious Department of Defense Physician Training Grant, the PCF Young Investigator Award, and the 2017 AUA-Urology Care Foundation Rising Star in Research Award. In 2020, Dr. Nguyen was awarded a $1 million Challenge Award from the Prostate Cancer Foundation and received the Benioff Initiative for Prostate Cancer Research grant to uncover novel molecular therapeutic targets for the treatment of metastatic prostate.

p_75

Peter H. O’Donnell, MD
Associate Professor of Medicine, Section of Hematology / Oncology,  Committee Chair, Committee on Clinical Pharmacology and Pharmacogenomics, The University of Chicago Chicago, IL

Dr. Peter O'Donnell, specializes in the treatment of genitourinary malignancies, including prostate, kidney, and testicular cancers — with particular expertise in bladder cancer. Dr. O'Donnell is a well-published researcher with advanced training in pharmacology and pharmacogenomics (the study of genetic traits that cause differences between patients in drug responses and side-effects). He has an interest in the study of personalized medicine, which involves considering each patient's genetic profile when determining chemotherapy and other therapeutic decisions. Dr. O'Donnell has several ongoing research projects. Currently, he is investigating how genetic factors affect chemotherapy drug outcomes — specifically for patients receiving treatment for bladder cancer, and for patients receiving the widely used chemotherapy drugs cisplatin and capecitabine. Additionally, Dr. O'Donnell serves as principal investigator of numerous clinical trials, including the "1200 Patients Project," a clinical study operated through the Center for Personalized Therapeutics at the University of Chicago. In this role, he leads an initiative exploring the benefit of incorporating broad pharmacogenomic testing into routine clinical practice for patients with any type of disease. Dr. O'Donnell is also a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. This committee aims to expand the educational mission of conducting research and training the next generation of scientists in clinical pharmacology, principles of therapeutics, molecular pharmacology, and pharmacogenomics.

p315

David Oh, MD, PhD
Assistant Professor, Medicine Principal Investigator, Assistant Professor In Residence University of California, San Francisco, San Francisco, CA

Dr. David Oh is an Assistant Professor in the Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco. He received his MD and PhD from Stanford, completed Medicine and Oncology housestaff training and a post-doctoral fellowship at UCSF, and has been on the faculty since 2018. He leads early-phase immunotherapy trials for solid tumors, with a particular focus on prostate, bladder, and kidney cancers, in the UCSF Cancer Immunotherapy Program. As the leader of the translational UCSF Cancer Immunotherapy Laboratory, he directs deep immune monitoring and functional validation of samples from immunotherapy-treated patients with genitourinary malignancies, to understand how immune fitness and specific novel immune functional states are linked to clinical response and toxicity with these agents. His work has been extramurally supported by the NIH, the Prostate Cancer Foundation, the Damon Runyon Cancer Research Foundation, the V Foundation, and the Department of Defense.

w13

Akash Patnaik, MD, PhD
Associate Professor of Medicine Deputy Section Chief for Translational Research Section of Hematology/Oncology Program Leader, Clinical & Experimental Therapeutics Program University of Chicago Comprehensive Cancer Center, Chicago, IL

Akash Patnaik, MD, PhD, MMSc, is a medical oncologist specializing in the care of patients with genitourinary cancers, including prostate, bladder, kidney and testicular cancers. He also has a strong interest in the development of novel therapeutics for treatment of advanced solid tumors. As an accomplished physician-scientist, Dr. Patnaik's work focuses on translating novel therapies from the laboratory to early stage clinical trials. He is interested in developing personalized patient models of disease in order to interpret therapeutics, develop biomarkers and help patients make informed decisions about their care. Dr. Patnaik has received numerous awards and recognition for his work, which include the John W. Kreider Ph.D. Commencement award in Cell & Molecular Biology, AACR-Astellas Clinical/Translational research award, Harvard-MIT Clinician-Investigator Training Program Fellowship, a Prostate Cancer Foundation Young Investigator Award and a DOD Prostate Cancer Physician-Researcher Training Award.

Mamta Parikh

Mamta Parikh, MD, MS
Associate Professor, UC Davis School of Medicine, Department of Internal Medicine, Division of Hematology Oncology, Medical Director, Genitourinary Malignancies, Associate Director of Curriculum Affairs, ARC-MD UC Davis Comprehensive Cancer Center, Sacramento, CA

Dr. Parikh is a medical oncologist specializing in the treatment of genitourinary malignancies, including bladder cancer, kidney cancer, prostate cancer, and testicular cancer. Dr. Parikh's research focuses on improving outcomes in bladder, kidney, and prostate cancer, by investigating new agents in clinical trials in patients with these malignancies, and by looking at cancer outcomes in California. She has clinical research interests in improving the effect of immunotherapy in bladder cancer. Dr. Parikh has graduated from the University of California Davis School of Medicine in 2011. Further she had completed her residency in internal medicine and fellowship in hematology/oncology from the University of California Davis School of Medicine in 2014 and 2017, respectively.

Petrylak

Daniel P. Petrylak, MD​
Professor of Medicine (Medical Oncology) and Urology​ Chief, Genitourinary Oncology​ Director of Genitourinary Oncology, Co Director Signal Transduction Program​ Yale School of Medicine​ New Haven, CT

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”​ ​ At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.​ ​ Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also the co-director of the Cancer Signaling Networks Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.​ ​ One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”​ ​ Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

quin

Qian Qin, MD
Assistant Professor, Department of Internal Medicine, UT Southwestern Medical Center​
Dallas, TX

Dr. Qin is a Medical Oncologist with a focus on genitourinary malignancies. She earned her undergraduate degree in Biological Sciences and Asian Studies at Rice University and medical degree at Baylor College of Medicine in Houston. She completed her residency in internal medicine at Houston Methodist Hospital and gained advanced training through a hematology and medical oncology fellowship at the Icahn School of Medicine at Mount Sinai in New York. Dr. Qin returned to Texas and joined UT Southwestern as Eugene P. Frenkel, M.D. Scholar in Clinical Medicine endowed Assistant Professor in the Department of Medicine, Division of Hematology and Medical Oncology. Her clinical specialization includes kidney, prostate, bladder, and testicular cancers and her research goals are to identify novel biomarkers, therapeutics, and therapeutic combinations in the setting of early phase clinical trials. Particularly, her current focus is on novel radiotracer-based biomarkers in genitourinary cancers, where she co-leads investigator initiated clinical trials in this space. Dr. Qin is also developing additional studies in prostate cancer with focuses on the use of PARP inhibitors in racial/ethnic minorities with homologous recombination repair alterations and kidney cancer with focus on tyrosine kinase inhibitor/immune checkpoint inhibitor combination in the peri- operative setting.

p_74

Arlene Siefker-Radtke, MD
Professor, Genitourinary Medical Oncology, UT MD Anderson Cancer Center, Houston, TX

Arlene Siefker-Radtke, MD is a Professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center. Her research focus is on developing effective therapies in the treatment of urothelial cancer and other rare tumors of the bladder and upper tract. She is well-known for her novel clinical trial designs, development of novel agents and targets including immunotherapy and cytokine analogues, FGFR inhibitors, development of neoadjuvant chemotherapy, and expertise in treating even those most rare tumors of the bladder.

www4

Melissa A. Reimers, MD
Associate Professor of Medicine, Clinical Director of Genitourinary Malignancies, Division of Oncology, Department of Internal Medicine, Washington University in St. Louis, Saint Louis, MO

Melissa Reimers is a genitourinary medical oncologist and Associate Professor of Medicine in the Division of Oncology at Washington University in St. Louis, where she is also Clinical Director of Genitourinary Malignancies. She has expertise in the clinical care of patients with bladder, kidney, and prostate cancer. She is currently Principal Investigator on multiple therapeutic interventional trials across the spectrum of genitourinary malignancies, and has a particular interest in clinical trial development for urothelial carcinoma.

p_23

Charles Ryan, MD
President and CEO, Prostate Cancer Foundation

Charles J. Ryan, MD, is the CEO of the Prostate Cancer Foundation. Dr. Ryan is an internationally recognized genitourinary (GU) oncologist with expertise in the biology and treatment of advanced disease as well as the supportive care of all men with prostate cancer. He was most recently the Director of the Hematology, Oncology and Transplantation Division in the Department of Medicine at the University of Minnesota, Minneapolis. He also served as the Associate Director for Clinical Research in the Masonic Cancer Center and held the B.J. Kennedy Chair in Clinical Medical Oncology. Dr. Ryan earned a BA in Philosophy, magna cum laude, from Marquette University and graduated from the University of Wisconsin Medical School. He trained at the University of Wisconsin Hospital and Clinics, serving as Chief Resident, and at Memorial Sloan Kettering Cancer Center in New York. Prior to moving to the University of Minnesota, he was on the faculty of the University of California, San Francisco, where he served as Program Leader for Genitourinary Medical Oncology and held the title of Thomas Perkins Distinguished Professor in Cancer Research. He has published over 200 articles and chapters in the world’s leading medical journals. He is the author of the book The Virility Paradox: The Vast Influence of Testosterone on Our Bodies, Minds, and the World We Live In, released in February 2018. Dr. Ryan is also the Leader of the Advanced Prostate Cancer Cadre in the Alliance for Clinical Trials in Oncology, a national clinical trials group, and past Chair of the NCI GU Steering Committee’s Prostate Cancer Task Force.

w14

Sarmad Sadeghi, MD, PhD
Associate Professor of Clinical Medicine and Urology Division of Medical Oncology
USC Institute of Urology Keck USC School of Medicine, University of Southern California, Los Angeles, CA

Dr. Sarmad Sadeghi earned his medical degree at Tehran University of Medical Sciences. He has a Master of Science degree (MS) in Health Information Sciences and a Doctor of Philosophy degree (PhD) in Public Health Management and Policy Sciences from the University of Texas Health Sciences Center at Houston. He completed his internal medicine residency at the University of Texas Medical School at Houston and the Cleveland Clinic Foundation. He completed his hematology/oncology fellowship at the Cleveland Clinic Taussig Cancer Institute. Dr. Sadeghi joined the faculty at the division of oncology of University of Southern California in 2013 and has a clinical and research focus in genitourinary malignancies, specifically bladder, kidney and prostate cancers. Dr. Sadeghi is the study chair and principal investigator of a number of multicenter clinical trials and is also an active member of SWOG cooperative group and the California Cancer Consortium. Dr. Sadeghi is well published with several original articles and abstracts in peer reviewed journals and international meetings.

p317

Amirali Salmasi, MD
Associate Professor, Department of Urology, Urologic Oncology, UC San Diego Health,
San Diego, CA

Amirali Salmasi, MD, is a urologist with expertise in the management of genitourinary cancers in men and women, including bladder, prostate, kidney, ureteral, testicular, adrenal, and penile cancers. He provides a personalized, multidisciplinary approach to deliver the best possible treatment options (active surveillance, focal therapy, surgery, radiation, systemic treatments, or clinical trials) for his patients. Dr. Salmasi performs advanced minimally invasive and complex open surgeries, such as robotic-assisted laparoscopic cystectomy, nerve-sparing prostatectomy, retro-peritoneal lymph node dissection, adrenalectomy, and partial nephrectomy. He is also interested in translational research and clinical trials in urologic oncology, and his hope is to bridge the gap between the bench and clinical research. He has published over 50 articles in peer-reviewed journals. Dr. Salmasi completed a urologic oncology fellowship at University of California, Los Angeles and a urology residency at Rutgers Robert Wood Johnson Medical School. As a first step towards a career in academic medicine and research, he also did a postdoctoral fellowship at Johns Hopkins School of Medicine. He earned his medical degree from Tehran University of Medical Sciences and holds a master's degree in clinical research (MSCR) from UCLA Clinical and Translational Science Institute. He is a member of the American Urological Association, the Society for Urologic Oncology and the American Society of Clinical Oncology.

p318

​​John Sarantopoulos, MD
Associate Professor, Peggy & Lowry Mays, Distinguished Chair, Hematology Oncology UT Health San Antonio, San Antonio, TX

Dr. John Sarantopoulos is a clinical research investigator and medical oncologist, with a full-time faculty appointment as associate professor of medicine in the division of hematology-oncology at The University of Texas Health Science Center San Antonio. His clinical interests and expertise are in early antineoplastic drug development and evaluation for human solid tumors including genitourinary malignancies of renal, prostate, bladder and melanoma. At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, he is involved with the early therapeutics phase I program, and is a member of the experimental developmental therapeutics program. Dr. Sarantopoulos completed an advanced drug development fellowship and is presently focusing on early phase I/II trials. He has been a co-principal investigator and principal investigator in over 54, phase I solid tumor studies, including first in human studies or first in class compounds, food effect or bioequivalence studies, drug interaction studies, QTc effect studies, and organ dysfunction studies, including renal and hepatic impairment. Studies have included National Cancer Institute cancer therapy evaluation program studies and the NCI organ dysfunction working group and cooperative group trials including the Southwest Oncology Group, where he is a member of the early therapeutics and genitourinary committees, as well as industry-sponsored and cancer center investigator-initiated trials. In addition, he has been a sub-investigator in over 139 trials in this area at the Mays Cancer Center over the last several years. Dr. Sarantopoulos’ education, clinical and research experiences place him in a select group of investigators that can complete complex early phase trials that are important to the development of new treatments for patients with cancer.

pictures14

A. Oliver Sartor, MD
Director, Radiopharmaceutical Trials, Mayo Clinic, Minnesota, FL 

Dr. Sartor received his MD from Tulane University School of Medicine with honors in 1982. After an internship at the University of Pennsylvania, he trained in internal medicine at Tulane Medical School. After completing a fellowship at the National Cancer Institute (NCI) in Bethesda, Maryland in 1989, he served until 1993 as a senior investigator at the NCI and began focusing on novel therapeutics for advanced prostate cancer patients. Dr. Sartor returned to Louisiana in 1993 to serve as an Associate Professor at the LSU Medical School in Shreveport and then moved to the LSU Health Sciences Center in New Orleans in 1998 as the Patricia Powers Strong Professor of Oncology, the Stanley S. Scott Cancer Center Director, and the Hematology/Oncology Section Chief. He was the Co-Director of the Louisiana Cancer Research Consortium, starting at its legislative inception in 2002. In March 2006, he left LSU to join the Lank Center for Genitourinary Oncology at the Dana Farber Cancer Institute and the Harvard Medical School. In January 2008, Dr. Sartor joined Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology. An internationally recognized expert in prostate cancer, Dr. Sartor’s interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer. Having published over 500 scholarly articles and having served as the past Chairman of the Department of Defense Prostate Integration Panel, Dr. Sartor, in addition to being the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology, is the Medical Oncology Chair of the GU Committee of the NRG, the Assistant Dean for Oncology at Tulane University School of Medicine, the Medical Director of the Tulane Cancer Center, and the Editor-in-Chief of the peer-reviewed journal, Clinical Genitourinary Cancer. In addition, he is currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).

p_73

Kerry Schaffer, MD
Assistant Professor,  Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN

Kerry Schaffer MD, is an Assistant Professor in the Department of Medicine, Vanderbilt Ingram Cancer Center.  She received her medical degree from University of Virgina School of Medicine, residency in Internal Medicine and fellowship in Hematology and Oncology from University of Rochester Medical Center. She is a clinician researcher and medical oncologist with an interest in prostate cancer genetics and developing novel prostate cancer therapeutics.   Outside of direct patient care, her research works to address gaps in health care delivery. 

pictures15

Laura Anne Sena, MD, PhD
Assistant Professor of Oncology, Johns Hopkins University, Baltimore, MD

Laura Sena, MD, PhD is a medical oncologist and an Assistant Professor of Oncology specializing in the care of patients with advanced prostate cancer at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University. She obtained her MD and PhD degrees from Northwestern University in the Medical Scientist Training Program, then subsequently completed Internal Medicine and Medical Oncology subspecialty training in the Physician Scientist Training Program at Johns Hopkins. The goal of her research is to improve therapies and outcomes for patients with advanced prostate cancer by better understanding how prostate cancer metabolism contributes to disease progression, therapeutic resistance, and tumor immune evasion.

p_82

​​Samer A. Srour, MB ChB, MS
Assistant Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center,  Houston, TX

Dr Srour is an Assistant Professor in the Department of Stem Cell Transplantation, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. He received his medical degree from Beirut Arab University. ​

p_25

Walter Stadler, MD, FACP
Fred C. Buffett Professor, Depts of Medicine & Surgery Dean for Clinical Research, Senior Advisor to the Director, Comprehensive Cancer Center UChicago Medicine,  Chicago, IL

Dr. Stadler is a clinical trialist who has focused on the development of novel therapies and biomarkers in genitourinary cancers. In this context, he has contributed to the development of gemcitabine in bladder cancer, VEGFR and PD1 checkpoint inhibitors in renal cancer, and various hormonal and other targeted therapies in prostate cancer. He has also explored novel trial designs for growth inhibitory agents, considered the necessary clinical characteristics of both molecular and imaging predictive biomarkers, co-authored consensus statements on prostate cancer clinical trial methodology, and is currently addressing novel pharmacologic approaches to mitigating the cost of care and patient financial toxicity. Because of his experience, he is a member of several data safety monitoring boards for international phase 3 trials. He has also built and led various clinical trial endeavors including leading the renal cancer cadre in the Cancer and Leukemia Group B (CALGB), building an infrastructure for coordinating multi-institutional clinical trials at the University of Chicago, leading a consortium of institutions to participate in the NCI Early Therapeutics Clinical Trial Network (ETCTN), leading the institutional effort as a lead site in the DOD funded Prostate Cancer Clinical Trials Network, and being the institutional lead for a collaborative multi-institutional Prostate Cancer SPORE. As the former Comprehensive Cancer Center Deputy Director and Program Leader for Clinical and Experimental Therapeutics, he has had a major role in growing clinical trial accrual to over 800 patients annually (of which 20% are underrepresented minorities), and contributed to planning and building outreach and population based research necessary for comprehensive status. As Dean for Clinical Research, he has been responsible for expanding clinical trials and clinical research activities throughout the enterprise across departments and centers as well as across the health system. He has enhanced the infrastructure and support, including informatics support, to provide the tools for faculty to conduct innovative clinical and translational research activities. These have, for example, led to the University of Chicago being a major site for accrual to COVID-19 vaccination studies with one of the highest accrual rates for underserved minorities in the nation.

pictures17

Cora N. Sternberg, MD
Clinical Director, Englander Institute for Precision Medicine, Professor of Medicine, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine,  New York, NY

Dr. Cora Sternberg is a leading international researcher and world expert in the field of medical oncology, genitourinary (GU) cancers, and drug development. Dr. Sternberg previously served as Chief of the Department of Medical Oncology at the San Camillo-Forlanini Hospital in Rome, Italy, and adjunct Professor of Oncology at La Sapienza University in Rome. A graduate of the University of Pennsylvania undergraduate and medical schools, Dr. Sternberg completed her fellowship and previously was on staff at Memorial Sloan Kettering Cancer Center. Dr. Sternberg helped develop the original M-VAC chemotherapy regimen, as well as the double-dose/high-dose/accelerated-dose M-VAC chemotherapy regimens in bladder and urothelial cancers. Additionally, Dr. Sternberg has served as principal investigator or been involved in numerous practice-changing studies for prostate cancer. These research efforts have led to the FDA approvals of abiraterone acetate and enzalutamide in advanced prostate cancer. Dr. Sternberg has been instrumental in the development of the drug Pazopanib, an antiangiogenic targeted therapy, for advanced clear cell renal cell carcinoma. She has also participated in the development of other antiagiogenic agents such as sunitinib, cabozantinib, tivozanib and dovitinib to treat renal cell cancer. At Weill Cornell Medicine and NewYork-Presbyterian Hospital, Dr. Sternberg will facilitate the continued growth and development of clinical and translational research programs in genitourinary (GU) malignancies, with a particular emphasis on expanding the breadth and depth of clinical and translational research. As Clinical Director of the Englander Institute for Precision Medicine (EIPM), Dr. Sternberg will develop strategies to incorporate genomic sequencing and precision medicine throughout the Weill Cornell Medicine and NewYork-Presbyterian healthcare network. Dr. Sternberg has published approximately 400 articles in peer-reviewed publications, including more than 100 first-authored articles. She has co-edited six textbooks, guest edited six others, and has published over 80 book chapters. Dr. Sternberg has lectured extensively at universities and cancer symposia worldwide, having given approximately 750 invited talks at prestigious international venues.

p6

Tyler F. Stewart, MD
Assistant Professor Medical Oncology,  University of California, San Diego, La Jolla, CA

Tyler Stewart is a genitourinary medical oncologist at the UC San Diego Moores Cancer Center and Assistant Professor of Medicine in the Division of Hematology and Oncology at the UC San Diego School of Medicine. His research focuses on clinical trials and translational studies in urologic malignancies, with a special focus in bladder/upper tract cancer. He serves as principal investigator for trials investigating novel therapeutics for advanced and locally advanced urothelial carcinoma. He also serves as principal investigator for multiple investigator initiated and industry-led trials investigating novel biomarkers in plasma and urine to detect minimal residual disease for genitourinary malignancies. He is an active member of the Alliance for Clinical Trials in Oncology cooperative group, and currently sits on the NCCN guidelines panel for bladder and penile cancer. Dr. Stewart is board certified in Medical Oncology and Internal Medicine. He received his medical degree from the University of Vermont College of Medicine and completed Internal Medicine Residency at UT Southwestern and Fellowship in Hematology and Medical Oncology at Yale University School of Medicine.

adyt5

Russell Szmulewitz, MD
Associate Professor of Medicine, Program Leader, Genitourinary Oncology, Section of Hematology/Oncology, Dept. of Medicine, The University of Chicago, Chicago, IL

Dr. Szmulewitz is a physician scientist whose primary academic focus is on characterizing and controlling the process of metastatic progression in men with prostate cancer. He received his medical degree from The University of Chicago, completed his residency from New York University Medical Center and fellowship from University of Chicago. He has a laboratory working with proteins called “metastasis suppressors” to slow down the growth of disseminated tumors in models of metastatic prostate cancer. In addition, Dr. Szmulewitz’s translational laboratory is using novel techniques to isolate and characterize prostate cancer cells from the blood of men with advanced prostate cancer. It is his goal to use these techniques to better personalize targeted therapies for metastatic prostate cancer.

adyt6

Nizar M. Tannir, MD, FACP
Professor Ransom Horne, Jr. Professor for Cancer Research RMC Alliance, Founder and President Department of Genitourinary Medical Oncology, Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX

Nizar M. Tannir, MD, FACP, is a Professor in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center where he holds the Endowed Ransom Horne, Jr. Professorship in Cancer Research. Dr. Tannir is nationally and internationally renowned for his expertise in kidney cancer. He is a clinical investigator with expertise in novel trial design, and has conducted numerous clinical trials in clear-cell renal cell carcinoma (RCC) and variant histology RCC. He is an expert on several rare kidney cancers, including translocation RCC (tRCC) and renal medullary carcinoma (RMC). He chairs a think-tank on RMC, and has brought together world experts from different fields to accelerate discovery and novel therapeutics for this devastating orphan cancer. Dr. Tannir has authored more than 320 original manuscripts and several book chapters. He edited Renal Cell Carcinoma, a book which was published by Oxford University Press in 2014, and Rare Kidney Tumors/A Multidisciplinary Approach, a book which was published by Springer in 2019. Dr. Tannir’s translational research is focused on deciphering the molecular underpinnings of RMC and tRCC and other rare RCC types such as collecting duct carcinoma. He has served as steering committee chair and global principal investigator of several industry sponsored trials. Dr. Tannir is Emeritus Member of the medical steering committee of the Kidney Cancer Association. Dr. Tannir was voted Teacher of The Year six times by the University of Texas MD Anderson Cancer Center Hematology-Oncology fellows. He also received numerous awards including the 2013 University of Texas MD Anderson Cancer Center Division of Cancer Medicine Gerald P. Bodey Award for Excellence in Education, the 2014 University of Texas MD Anderson Cancer Center Division of Cancer Medicine Waun Ki Hong Award for Leadership in Education, the 2014 University of Texas MD Anderson Cancer Center Division of Cancer Medicine Melvin L. Samuels Award for Excellence in Patient Care, the 2016 University of Texas Cancer Foundation Faculty Achievement Award in Patient Care, the 2020 University of Texas MD Anderson Cancer Center Distinguished Clinical Faculty Mentor Award, and the 2021 University of Texas MD Anderson Cancer Center Division of Cancer Medicine John Mendelsohn Lifetime Achievement Award. In 2017, Dr. Tannir received the Eugene P. Schonfeld Award from the Kidney Cancer Association for his research on rare kidney tumors and in 2023, he received the Nicholas J. Vogelzang Humanitarian Award also from the Kidney Cancer Association. Dr. Tannir has mentored over 45 fellows and junior faculty, many of whom have joined academic centers in the US and the rest of the world.

Taylor

Amy Taylor, MD​
Fellow Physician​ University of Wisconsin Carbone Cancer Center​, Madison, WI

p_210

Benjamin A. Teply, MD
Associate Professor, Division of Oncology & Hematology, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE

Dr. Teply is an Associate Professor in the Division of Hematology and Oncology at the University of Nebraska Medical Center. He completed Internal Medicine residency at the University of Michigan and a fellowship in medical oncology at Johns Hopkins University. His clinical expertise is in genitourinary medical oncology. Dr. Teply's research interests include novel hormonal and non-hormonal approaches in prostate cancer, novel biomarkers, optimal use of approved therapies, and clinical trials. Dr. Teply was recognized with UNMC's Internal Medicine 2021 award for excellence in clinical research, and he serves as the medical director for the Clinical Trials Office at the Buffett Cancer Center.

pictures19

​​Hong Truong, MD
Assistant Professor, Penn State Health, Hershey, PA

Dr. Hong Truong, MD is an Assistant Professor at Penn State Health Milton S. Hershey Medical Center. She eraned her medical degree from Jefferson Medical College (Pennsylvania). She then completed her residency from Urology Thomas Jefferson Univ Hospital and fellowship in Urologic Oncology Surgery from Memorial Sloan Kettering Cancer Center. Her research interest includes Bladder cancer, Cancer genetics, Clinical trials, Hereditary kidney cancer, Lynch syndrome, Mismatch repair deficiency, Precision medicine, Prostate cancer, Targeted therapy and Upper tract urothelial carcinoma. She has been awarded with ASCO Young Investigator Award (2021-2022), NIH T32 Ruth L. Kirschstein National Research Service Award (2020-2022) and many other awards.

pictures20

​​Mark Tyson, II, MD, MPH
Urologist Oncologist, Mayo Clinic, Phoenix, AZ

Mark Tyson, MD MPH, is a urologic oncologist in the Department of Urology at Mayo Clinic in Phoenix, Arizona. Dr. Tyson also serves as vice chair of research for the Department of Urology, vice chair of the Surgical and Procedural Committee, and chair of the Surgical Quality Subcommittee at Mayo Clinic in Arizona. Dr. Tyson joined the staff of Mayo Clinic in July 2017.​ ​ After receiving his M.D. from Dartmouth Medical School in Hanover, NH, Dr. Tyson completed his Urology residency at Mayo Clinic in Arizona, followed by a fellowship in Urologic Oncology at Vanderbilt University in Nashville, TN during which time he also completed an MPH with an emphasis in epidemiology and biostatistics from the Harvard T.H. Chan School of Public Health. He returned to Mayo Clinic in Arizona, where his clinical and academic subspecialty focus is on bladder cancer, and in particular orthotopic bladder substitution.​ ​ As a researcher, Dr. Tyson has focused predominantly on clinical trials and health services research as it relates to bladder cancer. He regularly publishes peer-reviewed manuscripts and has served on the editorial board of the Journal of Urology as an assistant editor.

p_27

Samir Zaidi, MD, PhD
Louis V. Gerstner Jr. Physician Scholar Assistant Attending, Genitourinary Oncology Service Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center,
New York, NY

Dr. Zaidi is a medical oncologist and Assistant Attending physician at Memorial Sloan Kettering Cancer Center. He is focused on providing care for patients with genitourinary malignancies. Dr. Zaidi also is dedicated to utilizing biological and computational tools to understand mechanisms underpinning oncologic and developmental disorders—a commitment that has been shaped by his prior training and experience. Dr. Zaidi worked first in the laboratory of Dr. Rudolf Jaenisch at MIT, where he studied stem cell reprogramming, and thereafter, in the laboratory of Dr. Richard Lifton at Yale during his MD/PhD, where he focused on the genetics of complex human diseases, notably congenital heart disease and neurodevelopmental disorders, as well as pulmonary, skin and skeletal diseases. During his medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC) in Sawyers lab, he investigated the mechanisms of lineage plasticity, a process by which tumor cells acquire different lineages to drive prostate cancer resistance, currently a therapeutic challenge. Dr. Zaidi has functionally and computationally analyzed its molecular underpinnings in dynamic models of lineage transition, including genetically–engineered mouse models (GEMMs) and murine and human tumor organoids. He has also analyzed the molecular architecture of biopsies from metastatic tumor undergoing lineage plasticity. Zaidi and colleagues found that the progression of plasticity depends on JAK/STAT and FGFR signaling, which is reversed by co-inhibition with FDA–approved drugs, ruxolitinib (JAK inhibitor) and erdafitinib (FGFR inhibitor). Zaidi continues to pursue his passion to explore the mechanisms of resistance in prostate cancer.

p321

​​Kevin K. Zarrabi, MD
Assistant Professor, Thomas Jefferson University, Philadelphia, PA 

Dr. Zarrabi is an assistant professor and medical oncologist at the Sidney Kimmel Cancer Center of Thomas Jefferson University in Philadelphia, PA. He specializes in genitourinary oncology with a focus on renal cell carcinoma, urothelial carcinoma, and prostate cancer. Dr. Zarrabi has published numerous articles pertaining to genitourinary malignancies. He is an active clinical researcher and has worked to design clinical studies and serves as an investigator on clinical trials within these disease spaces. Dr. Zarrabi completed his residency at Stony Brook University Hospital where he also served as chief resident. He then completed his hematology/oncology fellowship at Fox Chase Cancer Center.

p_83

Tian Zhang, MD, MHS
Associate Professor, Division of Hematology & Oncology, Department of Internal Medicine
UT Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center
Dallas, TX

Dr. Tian Zhang is an Associate Professor at UT Southwestern Medical Center. She specializes in the diagnosis and treatment of genitourinary malignancies, including kidney, prostate, bladder, and testicular cancers. Dr. Zhang earned her medical degree from the Harvard-MIT Health Sciences and Technology (HST) program at Harvard Medical School. She completed a residency in internal medicine at Duke University, where she also received advanced training through a hematology-oncology fellowship. In addition, she earned a Master of Health Sciences in the Clinical Research Training Program at Duke in 2019. She is certified by the American Board of Internal Medicine in medical oncology and joined the UT Southwestern faculty in 2021. Dr. Zhang is a clinical trialist and translational researcher focused on evaluating clinical development of novel therapeutics and evaluating biomarkers for genitourinary malignancies. She partners closely with a multidisciplinary team at UT Southwestern to provide data-driven clinical care for her patients. She has gained an international reputation developing clinical trials in kidney, prostate, and bladder cancers. She serves as the study chair for PDIGREE, a phase III trial in metastatic renal cell carcinoma. Dr. Zhang is a member of several professional organizations, including the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the European Society for Medical Oncology (ESMO). She serves on numerous committees, including as Co-chair of the National Cancer Institute Genitourinary (GU) Steering Committee Renal Task Force and as Chair of the Chinese American Hematologist and Oncologist Network (CAHON) Academic Committee. She is a member of several ASCO clinical management guidelines committees as well as the Alliance for Clinical Trials in Oncology, GU Oncology, and Immuno-Oncology Committees. She brings a track record of research and mentoring to UT Southwestern. She has received multiple peer-reviewed grants, a Resident Research Mentoring Award from Duke, and, notably, the 2021 Cancer Prevention & Research Institute of Texas (CPRIT) Scholar Rising Stars Award.

p322

Alexandre R. Zlotta, MD, PhD
Professor and Howard Sokolowski Chair in Uro-Oncological Research,  Department of Surgery (Urology), University of Toronto, Director, Uro-Oncology, Mount Sinai Hospital, Associate Scientist,  Lunenfeld-Tanenbaum Research Institute, Staff, Division of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

Dr. Alexandre Zlotta received his MD from the Free University of Brussels in 1989 and completed his Urology specialization as well as his PhD in Immunology in the same University. He worked as a Uro-Oncologist in the Department of Urology, Erasme Hospital, University Clinics of Brussels until 2006. In 2006, Dr. Zlotta was recruited to Toronto where he was appointed, and is currently, Professor in the Department of Surgery (Urology), University of Toronto, Director of Uro-Oncology, Mount Sinai Hospital, and surgeon at Princess Margaret Cancer Centre, University Health Network. He is also the Director of the Uro-Oncology Fellowship Program, University of Toronto and Director of the Bladder Cancer Research Program. Dr. Zlotta has served as Associate Editor to European Urology and is currently Consulting Editor for European Urology. He is also on several international editorial boards. In addition to being a surgeon, Dr. Zlotta is a translational research scientist with an extended research career that boasts success in both translational research and multi-institutional, international studies. He has a special interest in bladder and prostate cancer research where he has authored over 200 scientific papers. Dr. Zlotta is recognized with numerous awards, the most prestigious being the EAU Matula Award in 2000 and the EAU Platinum award in 2012.

​DAVA Oncology, 2700 W Plano PKWY, Plano, TX 75075, PH: 214-451-4500